Clinical trials in San Cristobal De La Laguna

Clinical trials in San Cristóbal de La Laguna are focusing on improving outcomes for patients with Age-Associated Macular Degeneration.

• Comparative effectiveness of anti‑VEGF agents such as ranibizumab and bevacizumab.
• Evaluation of genetic polymorphisms influencing drug response.
• Safety monitoring of emerging ocular therapies.
• Assessment of visual acuity preservation over a one‑year period.

The studies aim to refine therapeutic choices and personalize care for retinal disease.

Researchers are evaluating novel immunomodulators for conditions such as Sjögren’s Syndrome and Psoriatic Arthritis.

• Systemic symptom relief with targeted cytokine inhibitors.
• Long‑term safety and tolerability of oral Jak inhibitors.
• Biomarker‑driven patient stratification for personalized therapy.
• Impact on quality‑of‑life measures.

These trials seek to expand therapeutic options for autoimmune disorders.

Ongoing work addresses inflammatory joint disease, particularly Psoriatic Arthritis, through emerging biologic treatments.

• Evaluation of new biologic DMARDs versus standard care.
• Functional mobility outcomes in treated participants.
• Safety profile of combination therapy regimens.
• Patient‑reported pain and fatigue assessments.

The goal is to enhance disease control while minimizing adverse effects.

Oncology studies target small cell lung cancer and multiple myeloma, testing innovative combination regimens.

• Overall survival benefits of novel agent combinations.
• Induction therapy optimization for transplant‑ineligible myeloma patients.
• Safety profiling of antibody‑drug conjugates and targeted therapies.
• Immunophenotypic response evaluation at 18 months.

Efforts aim to improve survival rates and quality of life for cancer patients in the region.

Trials investigate metabolic health, including management of broad nutritional and metabolic diseases, with a focus on glycemic control.

• Superiority of immune‑targeting therapy for preserving insulin independence.
• Metabolic biomarker monitoring throughout study periods.
• Evaluation of patient‑reported outcomes related to daily functioning.
• Long‑term safety and tolerability assessments.

Researchers hope to identify strategies that reduce disease burden and delay complications.

Investigators are conducting antiviral studies for HIV, comparing new oral regimens to established therapies.

• Non‑inferior viral suppression rates with simplified dosing.
• Safety and tolerability of the two‑drug regimen.
• Resistance monitoring in antiretroviral‑naïve participants.
• Patient adherence and quality‑of‑life evaluation.

The aim is to broaden accessible treatment options for treatment‑naïve individuals.

Complementary research examines underlying immune mechanisms that drive autoimmune and cancer responses.

• Characterization of immune phenotypes in trial participants.
• Analysis of cytokine signaling pathways across disease cohorts.
• Integration of immunogenomic data to identify predictive biomarkers.
• Cross‑disease insights informing precision medicine approaches.

Insights from these studies may guide targeted therapies across multiple therapeutic areas.